fda compounding semaglutide warning september 2025 US removes suicidal thoughts from weight-loss drugs New project announcement: HHS‑OIG is

Popular pens include the Retatrutide 32 mg and 64 mg weight-loss pens, the NAD+ 1000 longevity pen, the GHK-Cu copper-peptide pen and the BPC-157 + TB-500 recovery pen

Do not stop taking Ozempic without consulting your healthcare provider

Novo and Lilly arent the only players in the field: candidates like orforglipron (a non-peptide oral GLP-1) and Vikings VK2735 (being developed in both oral and injectable forms) promise to broaden access and lower cost pressures

Adding Tesamorelin makes more sense if visceral fat reduction and body composition improvement are priorities beyond just scale weight

Unsurprisingly, it has been estimated that healthcare expenditure of European countries for overweight, obesity and related comorbidities might require approximately 8% of total national budgets between 2020 and 2050 4

Biochem Biophys Res Commun 298:779784 Mannucci E, Ognibene A, Cremasco F et al (2001) Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects